116870 ⎘
Hydrolases acting on peptide bonds, i.e. peptidases (3.4); Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
THROMBOLYTIC AGENTS FOR INTRAVASCULAR CLOTS
#2STROMA PENETRATING THERAPEUTIC T-CELL ENGAGER FOR CANCER IMMUNOTHERAPY
#3MODIFIED UROKINASE-TYPE PLASMINOGEN ACTIVATOR POLYPEPTIDES AND METHODS OF USE
#4CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#5TREATMENT FOR AIRWAY CAST OBSTRUCTION
#6DRUG REGIMEN FOR TREATMENT OF CEREBRAL ISCHEMIA
#7Nanoparticles Having Molecules That Bind or Block PD-L1 and Uses In Treating Cancer
#8CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#9CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#10CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#11FACTOR B PROTEASES
#12Nanoparticles having molecules that bind or block PD-L1 and uses in treating cancer
#13MIRAC PROTEINS
#14Fusion Proteins Having a Toxin and Cancer Marker, Nanoparticles, and Uses Related Thereto
#15MODIFIED UROKINASE-TYPE PLASMINOGEN ACTIVATOR POLYPEPTIDES AND METHODS OF USE
#16INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF
#17Thrombolytic Agents for Intravascular Clots
#18CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#19METHODS FOR SAFE AND EFFECTIVE THROMBOLYSIS USING SEQUENTIAL ADMINISTRATION OF TISSUE PLASMINOGEN ACTIVATOR AND MUTANT PRO-UROKINASE
#20Treatment for airway cast obstruction
#21Use of prourokinase and its variants against coagulopathy caused by viruses
#22Drug regimen for treatment of cerebral ischemia
#23MODIFIED UROKINASE-TYPE PLASMINOGEN ACTIVATOR POLYPEPTIDES AND METHODS OF USE
#24Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#25CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#26Fusion proteins having a toxin and cancer marker, nanoparticles, and uses related thereto
#27Drug regimen for treatment of cerebral ischemia
#28Modified urokinase-type plasminogen activator polypeptides and methods of use
#29METHODS AND COMPOSITIONS FOR MODULATING FGF23 LEVELS
#30Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#31Treatment for airway cast obstruction
#32Materials and methods for delivering compositions to selected tissues
#33Fumarylacetoacetate hydrolase (FAH)-deficient and immunodeficient rats and uses thereof
#34REDUCTION OF EGFR THERAPEUTIC TOXICITY
#35Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
#36Compositions and methods for administration of an enzyme to a subject's airway
#37METHOD FOR PREVENTING OR TREATING LIVER TISSUE DAMAGE AND ASSOCIATED DISEASES
#38Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#39Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#40Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#41Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#42RECOMBINANT SERINE PROTEASES
#43Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
#44Method of treating stroke by administering a compound that inhibits VEGF-B signaling in combination with a thrombolytic agent
#45Drug regimen for treatment of cerebral ischemia
#46COMPOSITIONS AND METHODS FOR ADMINISTRATION OF AN ENZYME TO A SUBJECT'S AIRWAY
#47Mirac proteins
#48STABLE INJECTABLE COMPOSITION OF PHARMACEUTICALLY ACTIVE AGENTS AND PROCESS FOR ITS PREPARATION
#49Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#50REDUCTION OF EGFR THERAPEUTIC TOXICITY
#51NORMALIZATION OF THE ENTEROHEPATIC CIRCULATION IN ANIMALS WITH A CHIMERIC HUMANIZED LIVER
#52Mirac proteins
#53Gelatinase inhibitors and prodrugs
#54Materials and methods for delivering compositions to selected tissues
#55COMPOSITIONS AND METHODS FOR ADMINISTRATION OF AN ENZYME TO A SUBJECT'S AIRWAY
#56Fumarylacetoacetate hydrolase (Fah)-deficient and immunodeficient rats and uses thereof
#57Integrated infusion container
#58METHODS AND COMPOSITIONS FOR MODULATING FGF23 LEVELS
#59Polymers for delivery of therapeutic proteins
#60Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
#61Treatment for airway cast obstruction
#62Diagnostic marker for treatment of cerebral ischemia
#63Gelatinase inhibitors and prodrugs
#64Mirac proteins
#65Mirac proteins
#66Mirac proteins
#67Polynucleotides encoding therapeutic inhibitors of PAI-1
#68Integrated infusion container
#69Protease screening methods and proteases identified thereby
#70Gelatinase inhibitors and prodrugs
#71Protease screening methods and proteases identified thereby
#72PROTEASE SCREENING METHODS AND PROTEASES IDENTIFIED THEREBY
#73LUBRICANT FOR WEAR TESTING OF JOINT REPLACEMENTS AND ASSOCIATED MATERIALS
#74Mirac proteins
#75Mirac proteins
#76MULTICISTRONIC siRNA CONSTRUCTS TO INHIBIT TUMORS
#77Molecular Determinants Associated With Prostate Cancer And Methods Of Use Thereof
#78Use of matrix metalloproteinase-10 (MMP-10) for thrombolytic treatments
#79C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
#80Anti-invasive and anti-angiogenic compositions
#81Polynucleotides encoding therapeutic inhibitors of PAI-1
#82CONJUGATES OF SOLUBLE PEPTIDIC COMPOUNDS WITH MEMBRANE-BINDING AGENTS
#83Mirac Proteins
#84MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES
#85Treating atherosclerosis
#86Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
#87Chimeric plasminogen activators and their pharmaceutical use
#88CRYSTAL STRUCTURE OF HUMAN UROKINASE PLASMINOGEN ACTIVATOR AMINO TEMINAL FRAGMENT BOUND TO ITS RECEPTOR
#89Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots
#90Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots
#91Anti-invasive and anti-angiogenic compositions
#92Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots
#93Protease screening methods and proteases identified thereby
#94Processed human chemokines PHC-1 and PHC-2
#95Targeting vector to the urokinase plasminogen activator receptor
#96Integrated infusion container
#97Lubricant for wear testing of joint replacements and associated materials
#98Multicistronic constructs with siRNA to inhibit tumors
#99Enzyme and Preparation Method
#100C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis
#101C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
#102Targeting of Herpes Simplex Virus to Specific Receptors
#103Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
#104Method for increasing the serum half-life of a biologically active molecule
#105Carrier chimeric proteins, targeted carrier chimeric proteins and preparation thereof
#106Method for increasing the serum half-life of a biologically active molecule
#107Erythropoietin: remodeling and glycoconjugation of erythropoietin
#108Methods for production of recombinant urokinase
#109Remodeling and glycoconjugation of peptides
#110Malarial animal model having a chimeric human liver
#111Cyclic peptidomimetic urokinase receptor antagonists
#112Tissue specific expression
#113Targeted adenovirus vectors for delivery of heterologous genes
#114DTAT fusion toxin
#115Method for increasing the serum half-life of a biologically active molecule
#116Compositions and methods for modulating muscle cell and tissue contractility
#117Pharmaceutical compositions of glycoconjugates
#118Cyclic peptidomimetic urokinase receptor antagonists
#119Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
#120Methods of making pro-urokinase mutants
#121Propagation of human hepatocytes in non-human animals